Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **gut microbiota–host epithelial surface interaction** encompasses the intricate and bidirectional relationship between the vast community of microorganisms residing in the gut (including bacteria, archaea, viruses, and fungi) and the epithelial lining of the gastrointestinal tract. This interaction maintains homeostasis by: - Supporting barrier integrity through regulation of tight junctions, mucin production, and antimicrobial peptide secretion - Modulating immune responses and inflammation - Influencing host metabolism and nutrient absorption via microbial metabolites (e.g., short-chain fatty acids, bile acids, indole derivatives) - Protecting against pathogen invasion Disruption of this relationship (dysbiosis or barrier dysfunction) is linked to diseases such as inflammatory bowel disease, colorectal cancer, infections, and metabolic disorders. Current research focuses on deciphering the molecular mechanisms underlying this crosstalk and developing strategies (such as probiotics, dietary interventions, and microbiome-modifying drugs) to restore or enhance beneficial host–microbe interactions[1][2][3][4][5].
null
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gut microbiota–host epithelial surface interaction (null).